Earlier this month, the US President signed a landmark executive order aimed at delivering “most favored nation” (MFN) pricing for prescription drugs in the United States. As outlined in the official White House release and covered by Reuters, the order seeks to tie US drug prices to those paid in other developed nations, potentially slashing prices by up to 59%. While much of the media focus has been on the implications for American patients, this shift also raises important

CSI’s Strategic Approach to Mitigating Clinical Trial Supply Disruption Recent developments in U.S. trade policy are shaking up supply chains, not just within the United States but worldwide. With the re-introduction of Trump-era tariffs on key goods, companies engaged in clinical research must rethink their sourcing and logistics strategies. Clinical Services International (CSI) is proactively addressing these challenges to support our clients amid this uncertain climate. Wh